Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1997-12-01
1999-01-12
Lankford, Jr., Leon B.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
424435, 424439, 424451, 424456, 514739, 514744, 514746, A61F 1300, A01N 3100, A61K 31045
Patent
active
058583890
ABSTRACT:
A method and composition for treatment of hepatitis C virus (HCV), administered as two component treatment, involving 1) an orally administered squalene in combination with 2) the inhalation of squalene medication. Each medication component must be administered concurrently.
REFERENCES:
patent: 5503828 (1996-04-01), Testa et al.
patent: 5529777 (1996-06-01), Andrianov et al.
patent: 5554372 (1996-09-01), Hunter
Purcell, R.H. Hepatitis C Virus; historical perspective and current concepts, FEMS Microbial Rev. 14, 181-192, (1994).
Van der Poel, C.L. Hepatitis C Virus. Epidemiology, transmission and prevention. In Hepatitis C Virus. Current Studies in Hematology and Blood Transfusion, H. W. Reesink ed. (Baset: Karger), pp. 137-163, (1994).
Love, R.A., Parge, H.E., Wickersham, J.A. Hostomsky, Z., Moomaw, E.W. and Hostomska, Z. in Agouron Pharmaceuticals, Inc. & Habuka, N. and Adachi, T. in Japan Tobacco, Inc. (Central Pharmaceutical Research Institute) and University of Tsukuba, Japan (Center for Tsukba Advanced Research Alliance). "The Crystal Structure of Hepatitis C Virus NS3 Proteinease Reaveals a Trypsin-like Fold and Structural Zink Binding Site," Cell, 87, 331-342, (1996).
Kim, J.L., Morgenstern, K.A., Lin, C., Fox, T., Dwyer, M.D., Landro, J.A., Chambers, S.P., Markland, W., Lepre, C.A. O'Malley, E.T., Harbeson, S.L., Caron, P.R. and Thompson, J.A. in Vertex PHarmaceuticals, Inc. & Rice, C.M. from Washington University, School of Medicin. "Crystal Structure of Hepatitis C Virus NS3 Protease Domain Complexed with Synthetic NS4A Cofactor Peptide." Cell, 87, 343-355, (1966).
Alter, M.J., and Maste, E.E. "The Epidemiology of Viral Hepatitis in the United States." Gastroenterol. Clin. North Am. 23, 437-455., (1994).
Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W. and Houghton, M. "Isolation of cDNA clone derived from blood-borne non-A, non-B viral hepatitis." Science, 244, 359-362, (1989).
Iwarson, S. "The natural course of chronic heaptitis," FEMS Microbial. Rev. 14, 201-204,(1994).
Alter, H.J., Purcell, R.H., Shih, J.W., Melpolder, J.C., Houghton, M., Choo, Q.L., and Kuo, G. "Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis." New Engl. J. Med. 321, 1494-1500, (1989).
Kuo, G., Choo, Q.L., Alter, H.J., Redeker, A.G., Purcell, R.H., Miyamura,T., Dienstag, J.L., Alter, M.J., Stevens, C.E., et al. "An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis." Science (1989).244, 362-364.
Renault, P.F., and Hoofnagle, J.H. "Side effects of alpha interferon." Semin. Liver Dis. 9, 273-277, (1989).
Statistical data from C&S Clinical Lab. Inc., P.O. Box 5269, Englewood, N.J. 07631-5269.
John Gerared, "The Herbal or General History of Plants" the complete 1633 edition is revised and enlarged by Thomas Johnson, Dover Pulbications Inc., NY (copyright 1975).
James Duke, "CRC Handbook of Medicinal Herbs", CRC Press Inc. Dated Jul. 24, 1986, Scientific Library Pat TM Office.
Kee Chang Huang, "The Pharmacology of Chinese Herbs", CRC Press Inc., (1993).
Schvarcz R.; Ando, Y., Sonnerborg, A. and Weiland, O.; Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: swedish experience. J Hepatol. 1995; 23 (Suppl 2): 17-21.
Van de Waterbeemd, H. "The History of Drug Research: from Hansch to Present." Quant. Struct.-Act. Relat. 11: 200-204, (1992).
Van de Waterbeemd, H. "Recent Progress in QSAR-Technology." Drug Des. Discov. 9: 227-285, (1993).
Stanon, D.T. Murray, W.J. and Jurs, P.C. "Comparison of QSAR and molecular similarity approaches for a stucture-activity relationships study of DHFR inhibitors." Quant. Struct.-Act. Relat. 12: 239-245, (1993).
Woldawer, A. and Erickson, J.W. "Structure-based inhibitors of HIV-1 protease."Annu. Rev. Biochem. 62: 543-585, (1993).
Tute, M.S. History and objectives of quantitative drug design. In Hansch, C., Sammes, P.G. and Taylor, J.B. (eds) Comperhensive Medicinal Chemistry, vol. 4, Quantitative Drug Design, pp. 1-31. Pergamon Press, New York (1990).
Hansch, C. The physicochemical approach to drug design and discovery (QSAR). Drug Rev. Res. 1: 267-309. (1981).
Hansch, C.On the state of QSAR. Drug Inf.J. 18:115-122, (1984).
Craig, P.N. QSAR-origins and present status: a historical perspective. Drug Inf.J. 18: 123-130, (1984).
Fujita, T. Application of quantitative structure-activity relationships in drug design. Acta Pharm. Jugosl. 37: 43-51, (1987).
Tsujimoto et al. Vaccine. vol. 7(1), pp. 39-48, Abstract enclosed, 1989.
Elsherbini Shaker H.
Lankford , Jr. Leon B.
Tate Christopher R.
LandOfFree
Squalene is an antiviral compound for treating hepatitis C virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Squalene is an antiviral compound for treating hepatitis C virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Squalene is an antiviral compound for treating hepatitis C virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1512271